Introduction
============

Pancreatic cancer (PC) is a lethal malignancy with an overall 5-year relative survival rate of 5%.[@b1-ott-10-5005] In 2015, an estimated 90,100 new patients were diagnosed with PC in China, with an estimated 79,400 deaths occurring as a result of delayed diagnosis and treatment resistance.[@b2-ott-10-5005] At the time of clinical diagnosis, most cancers are either locally advanced or metastatic, and surgical resection is very difficult.[@b3-ott-10-5005] In addition, PC is resistant to radiotherapy and chemotherapy.[@b4-ott-10-5005] One of the reasons that the PC responds poorly to treatment is due to its ability to evade host immune surveillance.[@b5-ott-10-5005] Emerging evidence has shown that the coinhibitory receptors, such as programmed death 1 (PD-1), play a critical role in cancer immunoediting.[@b6-ott-10-5005]

Programmed death-ligand 1 (PD-L1 or B7-H1), the major ligand for PD-1, plays a crucial role in PD-1-dependent immune suppression, which is mediated by an antigen-specific T-cell response.[@b7-ott-10-5005],[@b8-ott-10-5005] PD-L1 is expressed on various tumor cells, including PC cells, and immune cells, including activated CD4^+^ and CD8^+^ T cells, dendritic cells, macrophages, and regulatory T cells.[@b9-ott-10-5005]--[@b12-ott-10-5005] PD-L1 is not highly expressed in normal tissues; however, PD-L1 is upregulated in many tumors to attenuate the antitumor immune response via downregulating antitumor T-cell activity or suppressing apoptosis.[@b13-ott-10-5005]

Accumulating studies related to tumoral PD-L1 have been performed on malignancies, such as esophageal, liver, colorectal, breast, lung, glioblastoma, and blood cancers.[@b14-ott-10-5005]--[@b18-ott-10-5005] However, the prognostic role of PD-L1 is still debated. Overexpression of PD-L1 indicates a poor outcome in gastric cancer and non-small-cell lung cancer;[@b19-ott-10-5005],[@b20-ott-10-5005] in contrast, a better prognosis was observed in glioblastoma patients.[@b18-ott-10-5005] The association between aberrant PD-L1 expression and PC survival has also been evaluated. Due to the relatively small sample sizes, it is necessary to evaluate the association between PD-L1 and the prognosis of PC patients using a meta-analysis of a large cohort of up-to-date reports. In this study, we aimed to conduct a meta-analysis to reveal the association between PC and the clinicopathologic significance and prognostic value of PD-L1.

Materials and methods
=====================

Literature search strategy
--------------------------

A literature search was performed up to March 21, 2017, for published articles using the electronic databases PubMed, Web of Science, Scopus, and the Cochrane Library. We also searched the Chinese databases of Wanfang Data, China National Knowledge Infrastructure (CNKI), and SinoMed. Searches were limited to human studies without language restriction. The following terms and their combinations were searched in the title/abstract field: "programmed cell death-ligand 1", "PD-L1", "CD274", "B7-H1", "pancreatic cancer", and "pancreatic adenocarcinoma". We also carried out manual searches of references cited in the retrieved articles and preceding reviews. In addition, we searched meeting abstracts and virtual presentations of the American Society of Clinical Oncology annual meetings and the European Society of Medical Oncology congresses from 2010 to 2017.

Inclusion and exclusion criteria
--------------------------------

Qualified studies meeting the following eligibility criteria were included: 1) the histologic target was PC; 2) the association between PD-L1 expression, prognosis, and clinicopathologic features was investigated; 3) the expression of PD-L1 was categorized into high (positive) and low (negative) groups; and 4) relevant information could be acquired from the full-text study. Exclusion criteria included 1) duplicates, ongoing studies, letters, and reviews; 2) studies about PC cell lines, animal experiments, and other types of cancer; 3) studies not about PD-L1; and 4) incomplete data.

Data extraction and outcomes interest
-------------------------------------

Data from the included studies were acquired and summarized independently by two reviewers (Yongxun Zhuan-Sun and Fengting Huang). Disagreement was resolved by a discussion among the authors. The following information was extracted from the included studies: first author's name, year of publication, sample size, and survival time.

The primary outcome measure was the relationship between PD-L1 expression and overall survival. The secondary outcomes were the associations between PD-L1 expression and clinicopathologic characteristics.

Quality assessment and statistical analysis
-------------------------------------------

The quality of trials was evaluated by the Newcastle--Ottawa scale,[@b21-ott-10-5005] which consists of three factors: patient selection, comparability, and assessment of outcome. A score of 0--9 (allocated as stars) was allocated to each study; those that achieved six or more stars were considered to be high quality.

All the meta-analyses were performed by Review Manager 5.3 (Cochrane Collaboration, Oxford, UK). We addressed time-to-event outcomes by pooling hazard ratios (HRs) from Cox proportional hazards models. If the article supplied the HR with a 95% CI, we used the data. If the study did not supply the HR with a 95% CI, we calculated the HR and 95% CI according to Kaplan--Meier survival curves using Engauge Digitizer version 4.1 (Engauge Digitizer Software). The data were used following the method proposed by Tierney et al.[@b22-ott-10-5005] The generic inverse-variance method was performed to summarize the data. Pooled dichotomous data from other secondary outcomes were presented as risk ratios (RRs). Statistical heterogeneity between studies was assessed using chi-square tests with *P*\<0.10 as significance, and heterogeneity was quantified using the *I*^2^ statistic. The random-effects model was used if there was heterogeneity between studies; otherwise, the fixed-effects model was used.

Results
=======

Characteristics of included studies
-----------------------------------

A total of 10 studies including 1,058 PC patients were used in the final analysis. The initially included studies comprised seven from Asia and three from Europe. All of these studies were cohort studies. Eight articles were published in English and two were in Chinese. PD-L1 expression was examined by immunohistochemistry in eight studies, while the other two studies used quantitative reverse transcription polymerase chain reaction. Based on multivariate analysis, four studies[@b23-ott-10-5005]--[@b26-ott-10-5005] provided HRs with 95% CIs, while another five studies[@b27-ott-10-5005]--[@b31-ott-10-5005] provided survival curves with which to calculate HRs with 95% CIs. However, the remaining one study[@b32-ott-10-5005] provided neither survival curves nor HRs with 95% CIs and only provided the correlation between clinicopathologic characteristics and PD-L1 expression. Therefore, it was excluded from the overall survival analysis. The characteristics of the included studies are shown in [Table 1](#t1-ott-10-5005){ref-type="table"}.

Effect of PD-L1 expression on the overall survival of PC patients
-----------------------------------------------------------------

Nine studies were included. A fixed-effects model was applied in the meta-analysis for the HR, since the heterogeneity analysis showed that there was no significant heterogeneity among the studies (*I*^2^=0%, *P*=0.54). A significant difference was indicated by the pooled HR of 1.76 (95% CI: 1.43--2.17, *P*\<0.00001) between high and low PD-L1 expression groups ([Figure 1](#f1-ott-10-5005){ref-type="fig"}).

Correlation between PD-L1 expression and clinicopathologic characteristics
--------------------------------------------------------------------------

The clinicopathologic characteristics analyzed included tumor status, pathologic stage (TNM stage), metastatic status, differentiation, lymph node metastasis, vascular invasion, and neural invasion. Interestingly, high-level PD-L1 expression was correlated with poor differentiation (RR: 1.57, 95% CI: 1.25--1.98, *P*=0.0001) and neural invasion (RR: 1.30, 95% CI: 1.03--1.64, *P*=0.03), whereas other clinicopathologic characteristics were not significantly correlated with PD-L1 expression. The combined RRs for tumor status, pathologic (TNM) stage, metastatic status, lymph node metastasis, and vascular invasion were 1.04 (RR for higher tumor status, 95% CI: 0.85--1.27, *P*=0.74), 1.22 (RR for higher pathologic stage, 95% CI: 0.20--7.64, *P*=0.83), 1.40 (RR for M1, 95% CI: 0.88--2.23, *P*=0.16), 1.09 (RR for lymph node metastasis, 95% CI: 0.97--1.23, *P*=0.14), and 0.96 (RR for vascular invasion, 95% CI: 0.73--1.26, *P*=0.76), respectively ([Table 2](#t2-ott-10-5005){ref-type="table"}).

Subgroup analysis
-----------------

Subsequently, we carried out a subgroup analysis according to the methods detecting the expression of PD-L1. As shown in [Figure 2](#f2-ott-10-5005){ref-type="fig"}, a statistical significance of the pooled HR was observed in both the subgroup analyzed by polymerase chain reaction (HR: 2.24, 95% CI: 1.53--3.28, *P*\<0.0001) and the subgroup analyzed by immunohistochemistry (HR: 1.59, 95% CI: 1.23--2.04, *P*=0.0003) between high and low PD-L1 expression groups. The heterogeneity analysis detected no significant heterogeneity (*I*^2^=0%, *P*=0.54).

Publication bias
----------------

[Figure 3](#f3-ott-10-5005){ref-type="fig"} shows a funnel plot of the studies included in this meta-analysis, which illustrates the overall survival. There was no obvious publication bias.

Discussion
==========

To date, the association between PD-L1 and PC patients remains inconclusive.[@b24-ott-10-5005],[@b30-ott-10-5005],[@b33-ott-10-5005] Using meta-analysis, we examined data from a total of 1,058 patients from 10 independent studies.[@b23-ott-10-5005]--[@b32-ott-10-5005] We assessed the clinicopathologic significance and prognostic value of PD-L1 in PC patients. Intriguingly, the pooled results of our analysis showed that positive PD-L1 expression was highly correlated with a poorer overall survival in PC patients. Moreover, high-level PD-L1 expression was correlated with poor differentiation and neural invasion, which is in accordance with a study on lung adenocarcinoma.[@b34-ott-10-5005] However, the analysis found no significant correlations between PD-L1 expression and other clinicopathologic characteristics, including tumor status, pathologic (TNM) stage, metastatic status, lymph node metastasis, and vascular invasion.

Two previous meta-analyses evaluated the relationship of PD-L1 expression and survival in solid tumors and digestive system cancers, both of which included PC patients with a limited number of studies and participants.[@b35-ott-10-5005],[@b36-ott-10-5005] Our result was comparable to that of Dai et al who analyzed the survival in PC patients.[@b36-ott-10-5005] In addition, our data provided more reliable evidence with more participants and a lower publication bias. Moreover, we analyzed the correlations between PD-L1 expression and other clinicopathologic characteristics, which were not included in the two aforementioned meta-analyses.

Smoking contributes to tumor development and progression in various types of cancer, including lung cancer, oral squamous cell carcinoma, and PC.[@b37-ott-10-5005]--[@b39-ott-10-5005] Smoking cessation is one of the most effective strategies to reduce the risk of tumorigenicity. Interestingly, PD-L1 positivity is associated with smoking history in lung cancer and oral squamous cell carcinoma.[@b34-ott-10-5005],[@b40-ott-10-5005] High PD-L1 expression was a poor prognostic marker in the patients who were smokers, whereas this was not the case in those who never had a smoking habit among lung adenocarcinoma and oral squamous cell carcinoma patients.[@b40-ott-10-5005],[@b41-ott-10-5005] In addition, it was demonstrated that B7-H3, another member of the B7 family that is also known as an immune modulator, was associated with higher mortality in moderate/heavy smoking patients, but not in nonsmoking/light smoking patients in a study on lung adenocarcinoma.[@b42-ott-10-5005] It seemed that the impact of PD-L1 positivity on the survival in PC patients should be evaluated by stratification of smoking status. However, there were no data about the impact of PD-L1 positivity on the survival in PC patients stratified by smoking status in the studies included in this meta-analysis. Further studies are recommended to better interpret the impact of smoking on PD-L1 expression.

The molecular mechanism of overexpressed PD-L1 in PC remains obscure. Upregulation of PD-L1 could be stimulated by cytokines produced by infiltrating immune cells, such as interferon-γ (IFN-γ), interleukin (IL)-4, IL-10, vascular endothelial growth factor, and growth cell stem factor, in some solid tumors.[@b43-ott-10-5005]--[@b46-ott-10-5005] In addition, PD-L1 overexpression was observed in acute myeloid leukemia through IFN-γ or toll-like receptor stimulation in blast cells from patients via the mitogen-activated protein kinase kinase/extracellular signal-related kinase pathway and the myeloid primary differentiation response 88/tumor necrosis factor receptor-associated factor 6 pathway.[@b47-ott-10-5005] Moreover, constitutive oncogene pathway activation could also promote PD-L1 expression, for instance, in non-small-cell lung cancer, and specifically, the anaplastic lymphoma kinase/signal transducer and activator of transcription 3, phosphoinositide 3-kinase, and mitogen-activated protein kinase kinase/extracellular signal-related kinase/signal transducer and activator of transcription 1 pathways can activate PD-L1 expression.[@b48-ott-10-5005],[@b49-ott-10-5005] It was reported that the expression of PD-L1 in PC cells was induced via CD8^+^ T-cell IFN-γ-secretion.[@b50-ott-10-5005],[@b51-ott-10-5005] Therefore, PD-L1 expression might be modulated via different pathways among different tumor types.[@b43-ott-10-5005],[@b44-ott-10-5005],[@b49-ott-10-5005]

Due to conventional treatment resistance in PC, new immunotherapeutic strategies are urgently needed.[@b52-ott-10-5005],[@b53-ott-10-5005] Immunotherapy with immune checkpoint inhibition has shown promise as a therapeutic approach.[@b54-ott-10-5005] PD-L1, a critical immune checkpoint, is the primary PD-1 ligand, and it can decrease cytokine secretion and attenuate the biologic function of PD-1+ cells and tumor-infiltrating CD4^+^ and CD8^+^ T-cells.[@b55-ott-10-5005] These properties of PD-L1 may allow it to serve as a potentially promising target for cancer immunotherapy.[@b54-ott-10-5005] PD-L1 monoclonal antibodies exhibited an in vivo antitumor effect on murine PC by increasing CD8^+^ T-cell infiltration and triggering local immune function.[@b56-ott-10-5005] Furthermore, an effective outcome on murine PC was observed with the combined treatment of an anti-PD-L1 monoclonal antibody and gemcitabine. In addition, several clinical trials using an anti-PD-L1 monoclonal antibody, such as durvalumab and BMS-936559, were carried out and exhibited an appealing effect.[@b57-ott-10-5005]

High-level PD-L1 expression was correlated with a poorer overall survival in PC patients in our meta-analysis, which suggested that an anti-PD-L1 monoclonal antibody may be a new, promising treatment strategy for PC patients. Additional clinical trials are needed to evaluate the efficacy and safety of anti-PD-L1 monoclonal antibodies in patients with PC. The positive correlations between high-level PD-L1 expression and poor differentiation and PC neural invasion may provide an additional indication for the application of anti-PD-L1 treatment strategies for PC patients with poorly differentiated PC and neural invasion.

Despite the promising result from this meta-analysis, there are several limitations that need to be further addressed. First, the number of studies in this meta-analysis was moderate with limited statistical power. Second, some studies were not included due to a lack of data about the association between PD-L1 expression and clinicopathologic characteristics.[@b50-ott-10-5005],[@b58-ott-10-5005] Moreover, studies included in this meta-analysis were mostly single-center retrospective studies and did not include multicenter prospective cohort studies.[@b23-ott-10-5005],[@b29-ott-10-5005],[@b30-ott-10-5005] Finally, meta-analysis is a retrospective method that is subject to methodological limitations. Therefore, further studies are recommended to better interpret the available datasets.

Conclusion
==========

Our meta-analysis implied that PD-L1 may act as a negative predictor for the overall survival of PC patients, and high expression of PD-L1 was correlated with poor differentiation and neural invasion. However, further studies are recommended to better interpret the available datasets.
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![Forest plot and meta-analysis of the overall survival of the PD-L1 high expression group compared with the low expression group.\
**Note:** High PD-L1 expression was correlated with poorer overall survival in PC patients (HR: 1.76, 95% CI: 1.43--2.17, *P*\<0.00001).\
**Abbreviations:** *df*, degrees of freedom; HR, hazard ratio; IV, generic inverse variance method; PC, pancreatic cancer; PD-L1, programmed death-ligand 1; SE, standard error.](ott-10-5005Fig1){#f1-ott-10-5005}

![Subgroup analysis based on the methods used to detect PD-L1 expression.\
**Note:** A statistical significance of the pooled HR was observed in both the subgroup with PCR method (HR: 2.24, 95% CI: 1.53--3.28, *P*\<0.0001) and the subgroup with IHC method (HR: 1.59, 95% CI: 1.23--2.04, *P*=0.0003) between high and low PD-L1 expression groups.\
**Abbreviations:** *df*, degrees of freedom; HR, hazard ratio; IHC, immunohistochemistry; IV, generic inverse variance method; PCR, polymerase chain reaction; PD-L1, programmed death-ligand 1; SE, standard error.](ott-10-5005Fig2){#f2-ott-10-5005}

![Funnel plot illustrating the meta-analysis of the overall survival.\
**Note:** There was no obvious publication bias.\
**Abbreviations:** IHC, immunohistochemistry; PCR, polymerase chain reaction; SE, standard error.](ott-10-5005Fig3){#f3-ott-10-5005}

###### 

Characteristics of included studies

  Study                                    Region    Cancer type   Method    Cutoff                                                                                                 No of patients   Outcome   Quality score                
  ---------------------------------------- --------- ------------- --------- ------------------------------------------------------------------------------------------------------ ---------------- --------- ---------------------------- ----------------
  Birnbaum et al,[@b23-ott-10-5005] 2016   France    PC            qRT-PCR   Mean PD-L1 mRNA expression in normal pancreatic samples                                                87               366       OS and pathologic features   \*\*\*\*\*\*\*
  Chen et al,[@b27-ott-10-5005] 2014       China     PC            IHC       Cases with \>10% cells clearly stained were considered to be positive                                  24               39        OS and pathologic features   \*\*\*\*
  Chu et al,[@b32-ott-10-5005] 2011        China     PC            IHC       Staining score of ≥4 was considered to be positive[a](#tfn1-ott-10-5005){ref-type="table-fn"}          37               6         Pathologic features          \*\*\*\*
  Diana et al,[@b24-ott-10-5005] 2016      UK        PDAC          IHC       Median score value[b](#tfn2-ott-10-5005){ref-type="table-fn"}                                          41               104       OS and pathologic features   \*\*\*\*
  Liu et al,[@b28-ott-10-5005] 2016        China     PC            IHC       Cases with \>10% PD-L1-positive tumor cells were considered to be positive                             26               20        OS                           \*\*\*
  Loos et al,[@b29-ott-10-5005] 2008       Germany   PDAC          qRT-PCR   Median PD-L1 mRNA expression level                                                                     20               20        OS and pathologic features   \*\*\*
  Nomi et al,[@b30-ott-10-5005] 2007       Japan     PC            IHC       Specimens with a ≥10% PD-L1-positive tumor cells were classified as positive                           20               31        OS and pathologic features   \*\*\*
  Wang et al,[@b31-ott-10-5005] 2010       China     PC            IHC       Specimens with \>5% cells of the total tumor area stained positive were considered to be positive      40               41        OS and pathologic features   \*\*\*
  Wang et al,[@b26-ott-10-5005] 2017       China     PC            IHC       Staining score of ≥6 was considered to be high expression[a](#tfn1-ott-10-5005){ref-type="table-fn"}   27               67        OS and pathologic features   \*\*\*\*\*\*
  Yamaki et al,[@b25-ott-10-5005] 2017     Japan     PDAC          IHC       The threshold value for judging positive PID staining of PD-L1 was set to 3.0                          26               16        OS and pathologic features   \*\*\*\*\*

**Notes:**

PD-L1 staining scores were obtained by multiplying the staining intensities (0, negative; 1, weak; 2, medium; 3, strong) and the percentage of positive tumor (0, \<5%; 1, 5%--25%; 2, 26%--50%; 3, 51%--75%; 4, \>75%);

Scoring was based on the proportion of PD-L1-positive tumor cells: 1, absent cells, 2, \<25% cell density, 3, 25%--50% cell density, 4, \>50% cell density.

**Abbreviations:** IHC, immunohistochemistry; OS, overall survival; PC, pancreatic cancer; PDAC, pancreatic ductal adenocarcinoma; PD-L1, programmed death-ligand 1; qRT-PCR, quantitative reverse transcription polymerase chain reaction.

###### 

Meta-analysis: correlation between PD-L1 overexpression and clinicopathologic characteristics

  Outcomes of interest                                          No of studies   No of patients   RR    95% CI of RR   *P*-value    Study heterogeneity                   
  ------------------------------------------------------------- --------------- ---------------- ----- -------------- ------------ --------------------- ------ --- ---- -----------
  Tumor status                                                  6               188              410   1.04           0.85--1.27   0.74                  16.1   5   69   0.007
  Pathologic stage[a](#tfn4-ott-10-5005){ref-type="table-fn"}   3               97               78    1.22           0.20--7.64   0.83                  25.3   2   92   \<0.00001
  Metastatic status                                             4               97               152   1.40           0.88--2.23   0.16                  0.27   3   0    0.97
  Differentiation                                               6               218              406   1.57           1.25--1.98   0.0001                7.41   5   33   0.19
  Lymph node metastasis                                         7               224              414   1.09           0.97--1.23   0.14                  8.52   6   30   0.20
  Vascular invasion                                             3               105              176   0.96           0.73--1.26   0.76                  1.35   2   0    0.51
  Nervous invasion                                              4               145              217   1.30           1.03--1.64   0.03                  3.79   3   21   0.29

**Notes:**

Pathologic stage = TNM stage. RR was calculated for TNM stage III--IV.

**Abbreviations:** *df*, degrees of freedom; PD-L1, programmed death-ligand 1; RR, risk ratio.
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